432 related articles for article (PubMed ID: 16369727)
1. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis.
Friehs I; Margossian RE; Moran AM; Cao-Danh H; Moses MA; del Nido PJ
Basic Res Cardiol; 2006 May; 101(3):204-13. PubMed ID: 16369727
[TBL] [Abstract][Full Text] [Related]
2. Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury.
Friehs I; Moran AM; Stamm C; Choi YH; Cowan DB; McGowan FX; del Nido PJ
Ann Thorac Surg; 2004 Jun; 77(6):2004-10; discussion 2011. PubMed ID: 15172254
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor prevents apoptosis and preserves contractile function in hypertrophied infant heart.
Friehs I; Barillas R; Vasilyev NV; Roy N; McGowan FX; del Nido PJ
Circulation; 2006 Jul; 114(1 Suppl):I290-5. PubMed ID: 16820588
[TBL] [Abstract][Full Text] [Related]
4. Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy.
Nikolova A; Ablasser K; Wyler von Ballmoos MC; Poutias D; Kaza E; McGowan FX; Moses MA; Del Nido PJ; Friehs I
Ann Thorac Surg; 2012 Nov; 94(5):1509-17. PubMed ID: 22795062
[TBL] [Abstract][Full Text] [Related]
5. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females.
Voloshenyuk TG; Gardner JD
Am J Physiol Regul Integr Comp Physiol; 2010 Aug; 299(2):R683-93. PubMed ID: 20504902
[TBL] [Abstract][Full Text] [Related]
6. TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure.
Givvimani S; Kundu S; Narayanan N; Armaghan F; Qipshidze N; Pushpakumar S; Vacek TP; Tyagi SC
Arch Physiol Biochem; 2013 May; 119(2):65-74. PubMed ID: 23398532
[TBL] [Abstract][Full Text] [Related]
7. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
Kandalam V; Basu R; Abraham T; Wang X; Soloway PD; Jaworski DM; Oudit GY; Kassiri Z
Circ Res; 2010 Mar; 106(4):796-808. PubMed ID: 20056917
[TBL] [Abstract][Full Text] [Related]
8. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
[TBL] [Abstract][Full Text] [Related]
9. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure.
Givvimani S; Tyagi N; Sen U; Mishra PK; Qipshidze N; Munjal C; Vacek JC; Abe OA; Tyagi SC
Arch Physiol Biochem; 2010 May; 116(2):63-72. PubMed ID: 20230216
[TBL] [Abstract][Full Text] [Related]
10. Intramyocardial protein therapy with vascular endothelial growth factor (VEGF-165) induces functional angiogenesis in rat senescent myocardium.
Besse S; Boucher F; Linguet G; Riou L; De Leiris J; Riou B; Dimastromatteo J; Comte R; Courty J; Delbe J
J Physiol Pharmacol; 2010 Dec; 61(6):651-61. PubMed ID: 21224495
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload.
Zile MR; Baicu CF; Stroud RE; Van Laer AO; Jones JA; Patel R; Mukherjee R; Spinale FG
Circ Heart Fail; 2014 Mar; 7(2):340-50. PubMed ID: 24395927
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloprotease activity is enhanced in the compensated but not in the decompensated phase of pressure overload hypertrophy.
Tozzi R; Palladini G; Fallarini S; Nano R; Gatti C; Presotto C; Schiavone A; Micheletti R; Ferrari P; Fogari R; Perlini S
Am J Hypertens; 2007 Jun; 20(6):663-9. PubMed ID: 17531925
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium.
Kaza E; Ablasser K; Poutias D; Griffiths ER; Saad FA; Hofstaetter JG; del Nido PJ; Friehs I
Cardiovasc Res; 2011 Feb; 89(2):410-8. PubMed ID: 20935166
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
Truter SL; Catanzaro DF; Supino PG; Gupta A; Carter J; Herrold EM; Dumlao TF; Borer JS
Cardiology; 2009; 113(3):161-8. PubMed ID: 19129699
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.
Rengo G; Cannavo A; Liccardo D; Zincarelli C; de Lucia C; Pagano G; Komici K; Parisi V; Scala O; Agresta A; Rapacciuolo A; Perrone Filardi P; Ferrara N; Koch WJ; Trimarco B; Femminella GD; Leosco D
Circ Heart Fail; 2013 Nov; 6(6):1259-67. PubMed ID: 24029661
[TBL] [Abstract][Full Text] [Related]
16. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats.
Iwanaga Y; Aoyama T; Kihara Y; Onozawa Y; Yoneda T; Sasayama S
J Am Coll Cardiol; 2002 Apr; 39(8):1384-91. PubMed ID: 11955860
[TBL] [Abstract][Full Text] [Related]
17. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction.
Tessone A; Feinberg MS; Barbash IM; Reich R; Holbova R; Richmann M; Mardor Y; Leor J
Cardiovasc Drugs Ther; 2005 Dec; 19(6):383-90. PubMed ID: 16435072
[TBL] [Abstract][Full Text] [Related]
18. SI-27, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity: detection with a variable-pressure scanning electron microscope.
Yoshida D; Noha M; Watanabe K; Sugisaki Y; Teramoto A
Neurosurgery; 2002 Mar; 50(3):578-86; discussion 586-8. PubMed ID: 11841727
[TBL] [Abstract][Full Text] [Related]
19. Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase.
Stawowy P; Margeta C; Kallisch H; Seidah NG; Chrétien M; Fleck E; Graf K
Cardiovasc Res; 2004 Jul; 63(1):87-97. PubMed ID: 15194465
[TBL] [Abstract][Full Text] [Related]
20. Vascular Endothelial Growth Factor Prevents Endothelial-to-Mesenchymal Transition in Hypertrophy.
Illigens BM; Casar Berazaluce A; Poutias D; Gasser R; Del Nido PJ; Friehs I
Ann Thorac Surg; 2017 Sep; 104(3):932-939. PubMed ID: 28483153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
